Adamed plans to square up to Bioton with insulin purchase
"We are interested in the privatization of this firm due to its interesting product portfolio," said Anna Czajkowska, director for strategic planning and management board member of Adamed.
The investor is not discouraged by the disastrous financial condition of Polfa and the threat of its bankruptcy. "Despite that, we are awaiting the privatization even though that time plays against us, as the competition is not asleep and attractiveness of Polfa's portfolio is dropping from day to day," said Czajkowska.
Production insulin, and later other biotechnological products, are just an element of Adamed's strategy. It puts stress most of all on R&D. "Within five years we will have invested about zł.100 million in research from our own funds. We will also use EU funds. [...] We shall spend a further zł.35 million on research into innovative drugs in 2008. In the future, these expenditures would remain at least at the same level," said Czajkowska.
Source: Puls Biznesu (M.M.)
The investor is not discouraged by the disastrous financial condition of Polfa and the threat of its bankruptcy. "Despite that, we are awaiting the privatization even though that time plays against us, as the competition is not asleep and attractiveness of Polfa's portfolio is dropping from day to day," said Czajkowska.
Production insulin, and later other biotechnological products, are just an element of Adamed's strategy. It puts stress most of all on R&D. "Within five years we will have invested about zł.100 million in research from our own funds. We will also use EU funds. [...] We shall spend a further zł.35 million on research into innovative drugs in 2008. In the future, these expenditures would remain at least at the same level," said Czajkowska.
Source: Puls Biznesu (M.M.)
